GOG 120
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer (Gynecologic Oncology Group protocol 120)
N = 526
- Population
- Women with primary untreated invasive squamous-cell, adenosquamous or adenocarcinoma of the cervix, stage IIB, III or IVA, without para-aortic lymph-node involvement (526 women included in the analysis)
- Design
- Randomised trial of radiotherapy with one of three concurrent regimens: weekly cisplatin 40 mg/m2 for six weeks (group 1); cisplatin 50 mg/m2 on days 1 and 29 with a 96-hour fluorouracil infusion (4 g/m2) and oral hydroxyurea 2 g/m2 twice weekly for six weeks (group 2); or oral hydroxyurea 3 g/m2 twice weekly for six weeks (group 3). All patients had external-beam radiotherapy to a strict protocol.
- Arms
- Radiotherapy with weekly cisplatin (group 1) (experimental): External-beam radiotherapy with cisplatin 40 mg/m2 weekly for six weeks
- Radiotherapy with cisplatin, fluorouracil and hydroxyurea (group 2) (experimental): External-beam radiotherapy with cisplatin 50 mg/m2 (days 1 and 29), fluorouracil 4 g/m2 96-hour infusion, oral hydroxyurea 2 g/m2 twice weekly for six weeks
- Radiotherapy with hydroxyurea (group 3) (control): External-beam radiotherapy with oral hydroxyurea 3 g/m2 twice weekly for six weeks
- People
- Rose PG, senior author Insalaco S, Gynecologic Oncology Group